Results 231 to 240 of about 14,538,270 (379)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B. [PDF]

Blood Adv, 2023
Shapiro AD, Kulkarni R, Ragni MV, Chambost H, Mahlangu J, Oldenburg J, Nolan B, Ozelo MC, Foster MC, Willemze A, Barnowski C, Jain N, Winding B, Dumont J, Lethagen S, Barnes C, Pasi KJ.   +16 more
europepmc   +1 more source

The Malmo polymorphism of factor IX: establishing the genotypes by rapid analysis of DNA [PDF]

, 1989
Graham Jb, GR Kunkel, GS Tennyson, ST Lord, DM Fowlkes   +4 more
openalex   +1 more source

Evidence of clinically significant extravascular stores of factor IX

Journal of Thrombosis and Haemostasis, 2013
D. Feng, K. Stafford, G. Broze, D. Stafford   +3 more
semanticscholar   +1 more source

Hip morphology‐based osteoarthritis risk prediction models: development and external validation using individual participant data from the World COACH Consortium

Arthritis Care &Research, Accepted Article.
Objectives This study aims to develop hip morphology‐based radiographic hip osteoarthritis (RHOA) risk prediction models and investigates the added predictive value of hip morphology measurements and the generalizability to different populations. Methods We combined data from nine prospective cohort studies participating in the World COACH consortium ...
Myrthe A. van den Berg, Fleur Boel, Michiel M.A. van Buuren, Noortje S. Riedstra, Jinchi Tang, Harbeer Ahedi, Nigel K. Arden, Sita M.A. Bierma‐Zeinstra, Cindy G. Boer, Flavia M. Cicuttini, Timothy F. Cootes, David T. Felson, Willem Paul Gielis, Joshua Heerey, Graeme Jones, Stefan Kluzek, Nancy E. Lane, Claudia Lindner, Joyce B.J. van Meurs, Andrea Mosler, Amanda E. Nelson, Michael C. Nevitt, Edwin H. Oei, Jos Runhaar, Harrie Weinans, Jesse H. Krijthe, Rintje Agricola   +26 more
wiley   +1 more source

Factor IX and deep vein thrombosis

Haematologica, 2009
Gordon Lowe
doaj   +1 more source

Evaluation of One-Stage Assays for the Monitoring of Recombinant Human Factor IX Padua Activity After Etranacogene Dezaparvovec Gene Therapy. [PDF]

Haemophilia
Astermark J, Miesbach W, Coppens M, Gielen S, Twisk J, Dolmetsch R, Verweij S, Monahan PE, Ewenstein BM, Nuthalapati S, Galante N, Young G, HOPE‐B study investigators.   +12 more
europepmc   +1 more source

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand. [PDF]

Res Pract Thromb Haemost, 2023
Álvarez-Román MT, Shapiro AD, Ragni MV, Palmborg H, Bystrická L, Szamosi J, Casiano S, Chambost H.   +7 more
europepmc   +1 more source

Assessment of Pain Types in Recently Diagnosed Patients With Inflammatory Arthritis

Arthritis Care &Research, EarlyView.
Objective Up to 40% of patients with inflammatory arthritis (IA) experience persistent pain, traditionally thought to be associated with a shift from peripherally to centrally mediated pain during the disease course in some patients. We assessed sensory profiles of recently diagnosed individuals with IA, hypothesizing that pain reported at this early ...
Zoe Rutter‐Locher, Sam Norton, Joseph L. Taylor, Bina Menon, Tom Esterine, Ruth Williams, Leonie S. Taams, Kirsty Bannister, Bruce W. Kirkham   +8 more
wiley   +1 more source

Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa. [PDF]

, 1981
K M Braunstein, Claudia M. Noyes, Michael Griffith, Roger L. Lundblad, Harold R. Roberts   +4 more
openalex   +3 more sources

Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX-FP Prophylaxis in Hemophilia B: A Repeated Time-to-Event Analysis. [PDF]

Clin Pharmacol Ther
Koopman SF, Cnossen MH, Mathot RAA, OPTI‐CLOT study group and SYMPHONY consortium.   +3 more
europepmc   +1 more source